This trial is active, not recruiting.

Conditions autism, language acquisition, language development, toddlers
Sponsor National Institute of Mental Health (NIMH)
Start date April 2011
Trial size 77 participants
Trial identifier NCT01339767, 11-M-0144, 110144


The purpose of this study is to learn more about risk factors for autism by studying the behavior and brain functioning of toddlers with early communication delays and typically developing toddlers. Children 12 or 18 months of age with language delays (i.e., no words at 18 months, limited vocalizations at 12 months) and typically developing toddlers may be eligible to participate. This study will be conducted at the NIH Clinical Center in Bethesda, Maryland. There will be an initial screening evaluation that will include behavioral assessment. Eligible participants will then complete a baseline visit that includes an overnight sleep study that includes Electroencephalogram (EEG) test to measure brain electrical activity, and an MRI scan. Follow-up visits that include behavioral assessment will occur every 6-12 months, depending on age at study entry. The final study visit will occur at 36 months of age and will include behavioral assessment, sleep/EEG study, and MRI. There is no cost for participation. Compensation will be provided. To find out if your child qualifies or for more information, please call 301-451-7822 (TTY: 1-866-411-1010) or e-mail NIMH-ASD@mail.nih.gov. National Institute of Mental Health, National Institutes of Health, Department of Health & Human Services....

United States No locations recruiting
Other countries No locations recruiting

Study Design

Time perspective prospective

Eligibility Criteria

Male or female participants from 9 months up to 21 months old.

- INCLUSION CRITERIA: At-risk Group: 1. 12 or 18 months of age (plus or minus 3 months) 2. Limited spoken words (for both the 12 and 18 month groups) 3. Expressive and Receptive scores in the Very Low range on the Mullen Scales of Early Learning (a standardized observational measure), Typically Developing Group: 1. 12 or 18 months of age (plus or minor 3 months) 2. Development in nonverbal and verbal areas within age expectations (per scores on all 4 domains of the Mullen Scales of Early learning no more than 1.5 standard deviation below the mean). Healthy Adult Group: 1. 18-40 years old EXCLUSION CRITERIA: At-risk Group: 1. Primary language spoken in the home is other than English 2. Prematurity at birth (defined as less than 36 weeks gestation), or birth weight significantly below normal for gestational age (SGA- small for gestational age) or other significant birth trauma. 3. Motor or other medical impairment deemed responsible for delays (e.g. cerebral palsy; known genetic disorder) Typically Developing Group: 1. Primary language spoken in the home is other than English 2. Prematurity at birth (defined as less than 36 weeks gestation); or birth weight significantly below normal for gestational age (SGA- small for gestational age). 3. Motor or other medical impairment that would interfere with study participation 4. Known genetic disorder 5. Status as a younger sibling of a child diagnosed with autism Healthy Adult Group: 1. Historical or current psychiatric, neurological, or serious medical illness 2. Primary language is other than English 3. Difficulty hearing (as some sounds and words will be presented during the MRI scan) 4. Head injury with loss of consciousness in the last year 5. Metal in the body which would make having an MRI scan unsafe, such as pacemakers, medication pumps, aneurysm clips, metallic prostheses (including metal pins and rods, heart valves or cochlear implants), shrapnel fragments, permanent eye liner or small metal fragments in the eye that welders and other metal workers may have. 6. Discomfort in small closed spaces (have claustrophobia) so that there would be discomfort in the MRI machine. 7. Inability to lie comfortably flat on the back for up to 60 minutes in the MRI scanner 8. If female, and pregnant 9. Inability to provide own consent

Additional Information

Official title Markers of Autism Spectrum Disorders in At-Risk Toddlers: A Pilot Study
Principal investigator Audrey E Thurm, Ph.D.
Description Objective This investigation will focus on two areas: 1) early communication impairments as predictors of autism spectrum disorder (ASD) and later developmental delays, and 2) the relationship between communication and evidence of CNS function (sleep, EEG) and structure (MRI DTI and volumetrics) in young children at risk for ASD. The objective is to delineate early communicative impairments that predict ASD vs. other developmental delays and to examine how these impairments correlate with brain abnormalities in both structure and function. Study Population We will recruit 64 children [n=32 at 12 months of age (plus or minus 2 months); n=32 at 18 months of age (plus or minus 2 months)] who are at-risk for ASD due to communication/language delays (at-risk group). The at-risk children will be matched at initial on chronological age, SES, and sex, to typically developing children (n=75) with no history of developmental delays. These 139 participants will hereafter be referred to as the toddler sample. At the 36 month final visit, diagnostic status (e.g. ASD, non-ASD specific delays, catch up) will be determined for children in the at-risk group. In addition, 10 healthy adults, aged 18-40 will serve as control participants for the purpose of piloting the functional paradigms for the MRI portion of the protocol. Design We propose to conduct a prospective, longitudinal study of toddlers at-risk for ASD compared to typically developing toddlers. Children will complete behavioral testing and an overnight Sleep/EEG as well as MRI at either a 12 or 18 month initial. Follow-up visits that include behavioral assessment will occur at 24 and 36 months for all children (and at 18 months of age for the 12-month cohort). The Sleep/EEG and MRI will be repeated at the 36 month final follow-up. Outcome Measures Autism symptoms, language status, and cognitive development at 36 months will serve as the primary outcome measures.
Trial information was received from ClinicalTrials.gov and was last updated in August 2016.
Information provided to ClinicalTrials.gov by National Institutes of Health Clinical Center (CC).